The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Gilead Sciences, Inc. shares valued at $167,660 were sold by Parsey Merdad on Oct 01 ’24. At $83.83 per share, Parsey Merdad sold 2,000 shares. The insider’s holdings dropped to 100,189 shares worth approximately $8.89 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, MERDAD V PARSEY purchased 2,000 shares, netting a total of over 167,660 in proceeds.
Before that, Parsey Merdad had sold 21,246 shares from its account. In a trade valued at $1,795,287, the Chief Medical Officer traded Gilead Sciences, Inc. shares for $84.50 each. Upon closing the transaction, the insider’s holdings decreased to 21,246 shares, worth approximately $9.07 million.
As published in a research note from Leerink Partners on October 21, 2024, Gilead Sciences, Inc. [GILD] has been rated up from a Market perform to an Outperform and the price target has been revised to $96 from $74. Analysts at Bernstein started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid October. As of October 07, 2024, Wells Fargo has increased its “an Equal weight” rating to a “an Overweight” for GILD. Earlier on July 08, 2024, Raymond James upgraded its rating. Their new recommendation was “an Outperform” for GILD stock which previously was a “a Mkt perform”.
Analyzing GILD Stock Performance
During the last five days, there has been a surge of approximately 1.63%. Over the course of the year, Gilead Sciences, Inc. shares have jumped approximately 9.59%. Shares of the company reached a 52-week high of $89.21 on 10/24/24 and a 52-week low of $62.07 on 05/31/24. A 50-day SMA is recorded $82.07, while a 200-day SMA reached $74.09. Nevertheless, trading volume fell to 7.18 million shares from 4.37 million shares the previous day.
Support And Resistance Levels for Gilead Sciences, Inc. (GILD)
According to the 24-hour chart, there is a support level at 87.86, which, if violated, would cause prices to drop to 86.94. In the upper region, resistance lies at 89.46. The next price resistance is at 90.14. RSI (Relative Strength Index) is 69.04 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.80, which suggests the price will increase in the coming days. Percent R is at 8.61%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
